Photobiomodulation In Treatment Of Xerostomia In Type Ii Diabetic Patients

Hams Hamed Abdelrahman

Status

Completed

Conditions

Xerostomia

Diabetes Mellitus

Treatments

Other: Placebo Diode laser

Other: Diode Laser 980 nm, 0.2W

Study type

Interventional

Funder types

Other

Identifiers

NCT06703372

0404-9/22

Details and patient eligibility

About

Xerostomia is a major oral health problem that if not recognized and treated can have a significant effect on a patient's quality of life. It leads to difficulties with speech, swallowing and taste alteration. Pathological causes of xerostomia are divided into local and systemic factors. Local factors include smoking, salivary gland diseases and head and neck radiation therapy. Systemic factors include autoimmune diseases as Sjögren syndrome and hormonal disorders as Diabetes Mellitus. Photobiomodulation (PBM) previously known as Low Level Laser Therapy (LLLT) is the application of red and near infra-red light over injuries or lesions to improve wound and soft tissue healing, reduce inflammation and give relief for both acute and chronic pain. It also has grabbed the attention over the last few years as an effective treatment for xerostomia.

Enrollment

60 patients

Sex

All

Ages

25 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with type 2 diabetes mellitus suffering from xerostomia and on oral hypoglycemic drugs.
Glycated hemoglobin less than 7%.
Duration of diabetes mellitus not less than 4 years and not more than 8 years

Exclusion criteria

Patients receiving any drugs that cause hyposalivation.
Patients with any systemic disease reported to produce hyposalivation (sjogren's syndrome, hepatitis c, rheumatoid arthritis and lupus erythematosus).
Patients receiving chemotherapy and radiotherapy.
Individuals with skin lesions in the treatment zone to avoid any complications occurring in this area by laser exposure